These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23404126)

  • 1. Modeling NSCLC progression: recent advances and opportunities available.
    Suleiman AA; Nogova L; Fuhr U
    AAPS J; 2013 Apr; 15(2):542-50. PubMed ID: 23404126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
    Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
    BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKPD modeling of acquired resistance to anti-cancer drug treatment.
    Eigenmann MJ; Frances N; Lavé T; Walz AC
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):617-630. PubMed ID: 29090407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.
    Wang Y; Sung C; Dartois C; Ramchandani R; Booth BP; Rock E; Gobburu J
    Clin Pharmacol Ther; 2009 Aug; 86(2):167-74. PubMed ID: 19440187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
    Nishino M; Dahlberg SE; Cardarella S; Jackman DM; Rabin MS; Ramaiya NH; Hatabu H; Jänne PA; Johnson BE
    Cancer; 2013 Nov; 119(21):3761-8. PubMed ID: 23922022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
    Heon S; Yeap BY; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2010 Dec; 16(23):5873-82. PubMed ID: 21030498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan in the treatment of non-small cell lung cancer.
    Perez-Soler R
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-34-S20-41. PubMed ID: 9425959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
    Calhoun R; Jablons D; Lau D; Gandara DR
    Oncology (Williston Park); 2008 Apr; 22(5):511-6; discussion 516, 521-3. PubMed ID: 18533401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
    Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
    J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Jervine inhibits non-small cell lung cancer (NSCLC) progression by suppressing Hedgehog and AKT signaling via triggering autophagy-regulated apoptosis.
    Lei W; Huo Z
    Biochem Biophys Res Commun; 2020 Dec; 533(3):397-403. PubMed ID: 32972750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
    Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
    Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.
    Socinski MA; Govindan R; Spigel D
    Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 18):1-16. PubMed ID: 23187688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway.
    Wang WJ; Mao LF; Lai HL; Wang YW; Jiang ZB; Li W; Huang JM; Xie YJ; Xu C; Liu P; Li YM; Leung ELH; Yao XJ
    Pharmacol Res; 2020 Nov; 161():105129. PubMed ID: 32783976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
    Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
    PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ["Targeted Therapies" in NSCLC - present and future].
    Pall G; Hilbe W
    Wien Med Wochenschr; 2007; 157(21-22):545-53. PubMed ID: 18157592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.
    Tam TC; Ho JC; Wong MK; Wong WM; Wang JK; Lam JC; Lui MM; Lam WK; Ip MS; Lam DC
    Lung; 2013 Dec; 191(6):645-54. PubMed ID: 23929397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.